Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

By Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 743-753

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran: A Population Model Analysis

By Eriksson Ulf G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 7, 2003-01 ,pp. : 687-701

Adis International

Access to resources Recommend Favorite

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole

By Kivistö Kari T.   Wang Jun-Sheng   Backman Janne T.   Nyman Leena   Taavitsainen Päivi   Anttila Markku   Neuvonen Pertti J.  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 1, 2001-04 ,pp. : 37-42

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics, Preliminary Efficacy and Safety of Subcutaneous Melagatran and Oral Ximelagatran: A Multicentre Study of Thromboprophylaxis in Elective Abdominal Surgery

By Bergqvist D.  

Clinical Drug Investigation, Vol. 24, Iss. 3, 2004-01 ,pp. : 127-136

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite